Every 424B that Vaxcyte, Inc. (PCVX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow PCVX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PCVX filings page.
Vaxcyte, Inc. (PCVX) is offering $500 million aggregate principal amount of 1.50% convertible senior notes due October 15, 2032, with an underwriters’ option exercisable within 30 days to buy up to $75 million more solely to cover over-allotments. Estimated net proceeds are approximately $485.8 million, or $558.7 million if the option is fully exercised. The notes pay 1.50% annual interest semiannually beginning April 15, 2027; initial conversion terms are 11.1607 shares per $1,000 principal amount, approximately $89.60 per share. Conversion before July 15, 2032 is available only under specified conditions, and Vaxcyte may elect cash, shares or a combination to settle conversions.
Vaxcyte is also offering 7,412,500 common shares and pre-funded warrants to purchase 400,000 shares, plus an underwriter option for up to 1,171,875 more shares in a separate offering; neither offering is contingent on the other. Vaxcyte expected to report preliminary cash, cash equivalents and investments of approximately $2.3 billion as of September 30, 2026. In Phase 3 OPUS-1, VAX-31 met all prespecified co-primary immunogenicity endpoints in adults 50 and older and had a safety profile similar to PCV20 and PCV21; serotypes 3 and 12F versus PCV21 missed the prespecified noninferiority criterion but met the historical LBCI >0.5 threshold.
Vaxcyte, Inc. (PCVX) is offering 7,412,500 common shares and pre-funded warrants to purchase 400,000 shares, at $64.00 per share and $63.999 per warrant; the warrant exercise price is $0.001 per share. Estimated net proceeds are approximately $473.3 million, or approximately $544.3 million if underwriters fully exercise their option for 1,171,875 additional shares. Proceeds are intended to increase capitalization and financial flexibility.
A separate concurrent offering covers $500 million of 1.50% convertible senior notes due 2032, plus an underwriter option for up to $75 million; neither offering is contingent on the other. Preliminary, unaudited cash, cash equivalents and investments are expected to total approximately $2.3 billion as of September 30, 2026. In Phase 3 OPUS-1, VAX-31 met all prespecified co-primary immunogenicity endpoints in adults 50 and older; in adults 18–49, two PCV21-shared serotypes missed the prespecified noninferiority criterion but met the historical threshold. The stated net tangible book value dilution for new investors is $43.49 per share.
Vaxcyte, Inc. (PCVX) is offering convertible senior notes due 2032 alongside a separate common-stock or pre-funded-warrant offering; neither is contingent on the other. Cash interest is payable semiannually on April 15 and October 15, beginning April 15, 2027; the notes mature October 15, 2032 unless converted, redeemed or repurchased earlier. Conversion is limited to specified circumstances before July 15, 2032, and Vaxcyte may settle in cash, common stock or both. The notes are senior unsecured and structurally subordinated to subsidiary liabilities.
The offerings are intended to increase capitalization and financial flexibility. Vaxcyte expects approximately $2.3 billion in cash, cash equivalents and investments as of September 30, 2026, based on preliminary, unaudited information. No public market exists for the notes, and Vaxcyte does not intend to list them.
In Phase 3 OPUS-1, VAX-31 had a safety profile similar to PCV20 and PCV21 and met all co-primary immunogenicity endpoints in adults 50 and older. All 28 VAX-31 serotypes shared with PCV20 and/or PCV21 met prespecified noninferiority criteria. It met the primary immunobridging criterion in all 32 comparisons between adults aged 18–49 and 50–64; against PCV21, serotypes 3 and 12F missed the prespecified threshold but met the historical threshold.
Vaxcyte, Inc. (PCVX) is offering common stock and, for certain investors in lieu of shares, pre-funded warrants. Each warrant’s purchase price equals the public offering price per share minus $0.001, and its exercise price is $0.001 per share. Vaxcyte expects net proceeds from the offering; the stated principal purposes are to increase capitalization and financial flexibility. The concurrent convertible-note offering due 2032 is separate, and neither offering depends on completion of the other.
In Phase 3 OPUS-1, VAX-31 was well tolerated, with a safety profile similar to PCV20 and PCV21 at all ages studied. It met all prespecified co-primary immunogenicity endpoints in adults 50 and older, and all 28 serotypes shared with PCV20 and/or PCV21 met noninferiority criteria. The three VAX-31-unique serotypes and cross-reactive serotype 20B met the superiority criterion. Among adults 18–49, all 32 immunobridging comparisons met noninferiority; in comparisons with PCV21, 17 of 19 met the prespecified threshold, while serotypes 3 and 12F met the historical threshold.
Vaxcyte expects approximately $2.3 billion in cash, cash equivalents and investments as of September 30, 2026; the preliminary results are unaudited and not finalized.
Vaxcyte entered into a sales agreement on February 24, 2026 to sell up to $500.0 million of its common stock in an at-the-market offering through Leerink Partners LLC.
The sales agent may sell shares from time to time on mutually agreed terms and will receive a commission of up to 3.0% of gross proceeds. The prospectus cites the last reported sale price of $60.26 per share on February 23, 2026 and states 131,058,858 shares outstanding as of December 31, 2025. The supplement illustrates an example sale of 8,297,378 shares at $60.26 for aggregate gross proceeds of approximately $500.0 million, and shows dilution to new investors of $38.34 per share in that example.
Vaxcyte, Inc. is offering 11,000,000 shares of common stock at $50.00 per share, with gross proceeds of $550,000,000 and estimated net proceeds of about $521.9 million after fees and expenses.
The underwriters have a 30-day option to purchase up to 1,650,000 additional shares. As of September 30, 2025, Vaxcyte had 130,029,111 shares outstanding; after this offering, that figure would be 141,029,111 shares on an as-adjusted basis. The company reports preliminary cash, cash equivalents and investments of approximately $2.4 billion as of December 31, 2025, and its capitalization table shows cash, cash equivalents and investments increasing from $2,670.6 million to $3,192.4 million on an as-adjusted basis.
The offering creates immediate dilution for new investors: historical net tangible book value was $21.61 per share, rising to $23.62 per share after the deal, implying dilution of $26.38 per share at the $50.00 offering price. Vaxcyte plans to use the proceeds, together with existing cash, to fund its vaccine development programs and for general corporate purposes, while noting that the funds will not be sufficient to take any product candidate through regulatory approval.
Vaxcyte, Inc. plans a primary offering of common stock and pre-funded warrants, using a Nasdaq-listed common share price as the reference for warrant pricing. The pre-funded warrants carry a $0.001 exercise price and do not expire until fully exercised.
The company is a clinical-stage vaccine developer using a cell-free protein synthesis platform to design complex vaccines for serious bacterial diseases. It preliminarily expects to report about $2.4 billion in cash, cash equivalents and investments as of December 31, 2025 and intends to use new proceeds to strengthen its balance sheet and fund vaccine development programs.